INTRODUCTION
Pleurodesis is defined as the formation of a symphysis between the visceral and parietal pleura that prevents accumulation of air or liquid in the pleural space (1) . Pleurodesis is performed by introducing sclerosing agents into the pleural cavity or by surgical abrasion of the pleura (2) . Although a number of other sclerosing agents have been used for pleurodesis, talc is considered the best sclerosant based on success rates (3, 4) . Talc induces an intrapleural inflammatory response and plural fibrosis that obliterate the pleural space (2) .
Pleural changes after talc pleurodesis include pleural thicken-Purpose: To compare computed tomography (CT) and fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) findings of benign pleural changes with those of recurrent malignant pleural lesions in patients with a history of underlying malignancy after talc pleurodesis. Materials and Methods: Of 194 patients who underwent talc pleurodesis, we retrospectively reviewed 16 patients for whom both follow-up CT and FDG-PET/CT were performed. The morphologic CT findings and maximum standard uptake values (SUVmax) were evaluated and compared between benign pleural changes and recurrent malignant pleural lesions. Results: Twenty-two lesions were found in 16 patients; six patients had no evidence of active pleural disease (group 1) and 10 patients had recurrent malignant pleural lesions on radiological or clinical follow-up (group 2). Characteristic highdensity pleural deposits [mean, 131 Hounsfield unit (HU); range, 28-251 HU] were seen along the pleural thickenings (mean, 13.4 mm; range, 4.9-62.3 mm) in 15 patients. The shape and thickness on CT and the SUVmax on FDG-PET/CT showed no significant differences between the two groups. On CT, the pre-contrast attenuation was higher in group 1 than group 2 (165 HU vs. 101 HU, respectively, p = 0.030), and the degree of enhancement was higher in group 2 than that in group 1 (29 HU vs. 48 HU, respectively, p = 0.048). Pleural effusions (n = 5) and other pleural thickening without high-density foci (n = 4) were observed only in group 2; however, no statistical significance was observed between the two groups. Conclusion: Malignant pleural lesions can be characterized by lower pre-contrast attenuation and higher contrast enhancement, whereas benign pleural changes after talc pleurodesis are characterized by higher pre-contrast attenuation and lower contrast enhancement on CT. pleural lesion based on imaging studies and clinical follow-up of at least 6 months. The mean follow-up period for group 1 was 16 months (range, 6-23 months). Group 2 was confirmed to have recurrent malignant pleural lesions such as pleural or mediastinal invasion and metastasis based on clinical presentation and follow-up studies. The mean follow-up period of group 2 was 9 months (range, 4-16 months). Our institutional review board approved this retrospective study and did not require informed patient consent. 
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MATERIALS AND METHODS
Patients
From January 2004 to December 2011, 194 patients who had undergone talc pleurodesis at our institution were retrospectively reviewed. Of these, we enrolled 16 patients who had a history of malignancy and who underwent follow-up CT and FDG-PET/CT scans. The mean age of the study group was 54 years (range, 41-76 years). Eleven patients were male and five were female. The underlying malignancies were lung cancer (n = 13), malignant mesothelioma (n = 1), esophageal cancer (n = 1), and cervical cancer (n = 1). Patient characteristics are listed in Table   1 . Six patients had no evidence of active pleural disease (group 1) and 10 patients had recurrent malignant pleural lesions (group 2). Group 1 was pathologically confirmed by percutaneous needle biopsy (two patients) or clinically regarded as having benign conditions. Group 1 did not show evidence of recurrent 
RESULTS
Characteristic high-density pleural deposits with contrast enhancement on CT and increased uptake on FDG-PET/CT were seen along the pleural thickening in 15 patients (Fig. 1 ). The total number of pleural lesions was 22, and the mean number of pleural lesions per patient was 1.4 (range, 1-3). Five patients had two or more discontinuous lesions ( Fig. 2 ).
Shape
Of 22 pleural lesions, there were nodular patterns in three lesions (group 1, n = 2; group 2, n = 1), linear patterns in 10 (group 1, n = 5; group 2, n = 5), and patchy distributions in nine (group 1, n = 3; group 2, n = 6) ( Figs. 2, 3 ). The shapes of the pleural lesions are summarized in Table 2 . No significant differences were observed in lesion shape between groups 1 and 2 (p = 0.607).
Pleural Thickening
The thicknesses of the pleural lesions varied widely on CT (mean, 13.4 mm; range, 4.9-62.3 mm). The mean thicknesses of the pleural lesions were 11.7 mm (range, 7.0-16.9 mm) and 14.8 mm (range, 4.9-62.3 mm) in groups 1 and 2, respectively. No significant differences were observed in pleural thickening be-transverse field of view. PET datasets were obtained via iterative reconstruction with an ordered subset expectation maximization algorithm and by the application of segmented attenuation correction (two iterations, 28 subsets) to CT data. Co-registered scans were displayed using software that enabled image fusion and analysis.
Imaging Analysis
Imaging analyses were performed using morphologic CT findings including shape (nodular, linear, and patchy), thickness (mm), average attenuation [Hounsfield unit (HU)], and degree of enhancement (HU) of the pleural lesions. Attenuation (HU) was measured using the elliptical region of interest (ROI) around high-density pleural lesions, and the degrees of enhancement were recorded as the difference in attenuation between enhanced and non-enhanced images. The highest metabolic activity was evaluated using measurements of maximum standard uptake values (SUVmax) within the same ROI used for the average attenuation measurements. When a patient had two or more discontinuous lesions, images were separately evaluated for each lesion. All measured values were compared between groups 1 and 2.
Statistical Analysis
Differences in lesion shape and additional findings between groups 1 and 2 were assessed using Fisher' s exact test. The Mann-Whitney U-test was used to compare thickness, attenuation, degree of enhancement, and SUVmax. p-values < 0.05 were considered significant. Statistical analysis was performed using PASW statistics 20 (SPSS Inc., Chicago, IL, USA). spectively.
Maximum Standard Uptake Value
The areas of SUVmax corresponded to high attenuation pleural abnormalities in all lesions (mean, 12.04; range, 4.34-42.65). The mean SUVmax of pleural lesions was 10.89 (range, 7.74-18.25) and 12.99 (range, 4.34-42.65) in groups 1 and 2, respectively. No significant differences were observed between the groups (p = 0.598). Values for pleural thickening, attenuation, degree of enhancement and SUVmax are summarized in Table 3 .
Additional Findings
Pleural effusions (n = 5) and other pleural thickenings without high-density foci (n = 4) were seen only in group 2 (Fig. 4) .
However, the frequencies of pleural effusion and other pleural thickening were not significantly higher in group 2 than those in group 1 (pleural effusion, p = 0.093; other pleural thickening, p = 0.234) ( Table 3) . tween the groups (p = 0.356).
Attenuation and Enhancement
The majority of pleural abnormalities were associated with areas of high attenuation (mean, 131 HU; range, 28-251 HU).
The mean attenuations of the pleural lesions were 166 HU (range, 65-251 HU) in group 1 and 101 HU (range, 28-218 HU) in group 2. Attenuation of pleural lesions was significantly higher in group 1 than that in group 2 (p = 0.030). After contrast administration, all pleural lesions except two showed increased attenuation of 20 HU or more. One of the two unusual lesions belonged to group 1, and the other belonged to group 2.
The mean degree of enhancement for all lesions was 40 HU (range, 5-73 HU). Although most pleural lesions showed contrast enhancement, the degree of enhancement was significantly higher in group 2 than that in group 1 (p = 0.048) (Fig. 3) .
The mean degree of enhancement was 29 HU (range, 5-62 HU) and 48 HU (range, 12-73 HU) in group 1 and group 2, re- Granulomatous giant cell reactions surrounding talc crystals in the pleura have been described in recent studies (6, 19) . Most deposits have been described as linear or nodular pleural lesions (2, 5) . Similar morphological findings were also ob- contrast attenuation and lower contrast enhancement on CT.
Our findings may help clinicians distinguish recurrent malignant pleural lesions from benign inflammatory processes after talc pleurodesis in patients with a history of malignancy. take (11) . Increased FDG uptake is persistent after talc pleurodesis, which indicates chronic influx and efflux of inflammatory cells (14) . The stability of talc lesions on PET and PET/CT scan has been observed in case reports of patients followed for up to 42 years after talc pleurodesis (8-12, 15, 16, 20) .
CT appearance after talc pleurodesis may simulate other conditions such as recurrence or metastasis, particularly in patients with a history of malignancy. Characteristic pleural thickening with high attenuation and a history of pleurodesis helps clinicians differentiate talc deposits from diverse pleural abnormalities (2) . The use of FDG-PET/CT to distinguish malignant pleural involvement from benign inflammatory processes after talc pleurodesis remains challenging. Pleural lesions with increased FDG uptake that correspond to high attenuation on CT in patients with a history of talc pleurodesis is a typical finding of reactive inflammation (21) . In contrast, pleural lesions without high-density foci associated with FDG uptake in follow-up studies should raise suspicion for malignant lesions.
In our study, pleural effusions and other pleural thickenings without high-density foci were seen only in the recurrent malignant group. Although the frequencies were not statistically significant between the two groups, we believe that these additional findings can be used to distinguish recurrent malignant lesions from benign pleural changes after talc pleurodesis.
Our study had limitations. First, it was a retrospective analysis of a small patient sample. Second, only two patients had histologically proven diagnoses by percutaneous biopsy. In the remaining patients, the lesions were assumed to be benign or malignant on the basis of follow-up imaging and clinical findings. Although not ideal, this is a recognized method for assessing pleural recurrence or metastasis. Third, we regarded the tumors as benign or malignant without confirming each lesion in patients with multiple lesions, which is a considerable weakness because benign and malignant lesions may exist concurrently in one patient.
In conclusion, pleural changes after talc pleurodesis are revealed as high-density pleural thickening with increased FDG uptake in both benign inflammatory processes and malignant lesions in patients with a history of malignancy. Malignant pleural lesions were characterized by lower pre-contrast attenuation and higher contrast enhancement, whereas benign pleural changes after talc pleurodesis were characterized by higher pre-
